7月3日，港股创新药概念涨幅扩大，中证香港创新药指数涨超3%，成分股康方生物涨10%，信达生物 涨7%，荣昌生物涨6%，带动港股创新药ETF（513120）早盘涨超3%，成交额已超65亿元，较前5个交 易日显著放量，实时成交额持续位居全市场权益类ETF首位。Wind数据显示，港股创新药ETF （513120）最新规模超137亿元，是全市场规模最大的港股创新药主题指数基金。 消息面上，近日，国家医保局、国家卫生健康委联合印发《支持创新药高质量发展的若干措施》，从研 发、准入、入院使用、多元支付等环节提出16条具体支持政策，标志着我国创新药产业步入系统性扶持 新阶段。江海证券分析指出，随着政策落地深化，将加速行业从"仿创"向"首创"转型，具备全球化布局 和细分领域创新能力的药企或率先受益。 资金也在加速布局创新药板块。截至7月2日，港股创新药ETF（513120）近5个交易日累计获净流入3.11 亿元，最新规模达137.44亿元，创近一年新高，稳居全市场医药类ETF规模榜首。流动性方面，该ETF 近1月日均成交70.30亿元，居同类产品第一，其T+0交易机制进一步提升了资金效率。从业绩表现看， 该ETF近一年回报 ...

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling below the 24,000-point mark, while biotechnology stocks showed strength [1] Group 1: Market Performance - The Hang Seng Index dropped by 0.96% by midday, while the Hang Seng Tech Index fell by 1.2% [1] - The market opened high but saw a decline, with the Hang Seng Index initially down over 1.2% and the Hang Seng Tech Index down over 1.4% [1] Group 2: Sector Performance - Online retail stocks declined, with Alibaba (09988.HK) falling over 3%, and Meituan (03690.HK) and JD.com (09618.HK) both dropping over 2% [1] - The pharmaceutical and biotechnology sectors saw gains, with Basestone Pharmaceuticals (02616.HK) and Kangfang Biotech (09926.HK) both rising over 10% [1] - Other popular tech stocks also faced declines, with Xiaomi Group (01810.HK) down over 4%, Kingsoft (03888.HK) down 7.58%, and Bilibili (09626.HK), Kuaishou (01024.HK), and Trip.com Group (09961.HK) all down over 1% [1]

港股午间收盘，恒生指数跌0.96%，恒生科技指数跌1.2%。港股医药股再度走强，华昊中天医药涨超 17%，康方生物涨超11%。港股科网股多数走低，金山软件跌超7%，小米集团跌超4%，阿里巴巴跌超 3%。 ...

Group 1: Market Performance - The Hang Seng Medical ETF (513060) opened high and experienced a nearly 2% increase during the session, with a trading volume close to 1.8 billion and a turnover rate exceeding 20%, indicating active trading [1] - More than half of the constituent stocks rose, with notable increases such as Ascentage Pharma-B up over 6%, and other companies like Innovent Biologics and WuXi AppTec also showing significant gains [1] Group 2: Policy Impact - The National Healthcare Security Administration recently issued guidelines for the adjustment of the basic medical insurance directory and the commercial insurance innovative drug directory, marking a significant step for commercial health insurance in the multi-level medical security system [1][2] - The inclusion of the commercial health insurance innovative drug directory is expected to enhance the role of commercial insurance in the multi-level medical security system, providing more opportunities for the industry [1][2] Group 3: Innovation Drug Development - From 2018 to 2024, the number of Class 1 innovative drugs approved in China has shown a significant upward trend, with 48 drugs expected to be approved in 2024, more than five times that of 2018 [2] - The introduction of measures to support innovative drug development aims to guide the biopharmaceutical industry and avoid excessive competition, promoting high-quality development of innovative drugs [2][3] Group 4: Payment and Application Mechanisms - The establishment of a "commercial health insurance innovative drug directory" is expected to create a tiered security mechanism that promotes the global market development of innovative drugs [3] - Specific measures include optimizing the drug listing process and encouraging the use of innovative drugs in designated medical institutions, which will enhance the efficiency of the entire process [6][7] Group 5: Investment Opportunities - The Hang Seng Medical ETF is positioned as a core vehicle for investing in the turning point of innovative drugs, benefiting from policy support and historical valuation gaps [8] - The ETF's underlying assets include leading companies that are expected to benefit from payment reforms and the commercial insurance directory, indicating a potential for cash flow stability and valuation recovery [8]

Group 1 - The core viewpoint of the article highlights the positive market atmosphere created by the trade agreement between the US and Vietnam, leading to a collective rise in the Hong Kong stock market [1] - The Hong Kong Stock Connect Technology ETF (513860) experienced a slight decline of 0.56% as of 10:35 AM, despite having gained over 4% last week and nearly 30% year-to-date [1] - Notable stock performances include a rise of over 7% for companies like Innovent Biologics and CanSino Biologics, while companies such as Kelun-Biotech and Zai Lab saw increases of over 6% [1] Group 2 - The Hong Kong Monetary Authority (HKMA) intervened in the market by selling US dollars and buying Hong Kong dollars, involving an amount of HKD 20.018 billion to stabilize the currency [1] - The total bank system surplus has decreased to HKD 144.1 billion, following a cumulative purchase of approximately HKD 30 billion by the HKMA from June 26 to July 2 [1] - The Hibor rate has dropped from 4.5% to 0.4%, indicating a significant change in the liquidity environment [1] Group 3 - Goldman Sachs indicated a strong interest from investors in the Hong Kong market and Hong Kong dollar assets, with a relatively abundant liquidity environment [1] - The Hong Kong IPO market remains active without causing liquidity issues, and there is an increasing demand for the Hong Kong dollar from overseas investors [1] - The top ten weighted stocks in the Hong Kong Stock Connect Technology ETF (513860) account for 69.41% of the index, including major companies like Xiaomi, Tencent, and BYD [1]

创新药概念港股涨幅扩大。截至发稿， 基石药业(02616.HK)涨12%， 康方生物(09926.HK)涨10%， 信 达生物(01801.HK)涨7%， 荣昌生物(09995.HK)涨6%。 ...

Core Viewpoint - The Hang Seng Healthcare Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the healthcare sector [1][2]. Group 1: Market Performance - As of July 3, 2025, the Hang Seng Healthcare Index rose by 1.67%, with notable gains from stocks such as Huahao Zhongtian Pharmaceutical-B (+16.97%) and Ascentage Pharma-B (+7.11%) [1]. - The Hang Seng Healthcare ETF (Jia Shi, 159557) increased by 1.48% [1]. - The ETF recorded a turnover of 6.64% and a transaction volume of 21.35 million yuan, with an average daily transaction volume of 46.55 million yuan over the past month [2]. Group 2: Fund Performance - The latest scale of the Hang Seng Healthcare ETF reached 315 million yuan, marking a one-year high, with the latest share count at 221 million, also a three-month high [2]. - The ETF has seen a net inflow of 2.048 million yuan recently [2]. - Over the past year, the net value of the ETF has increased by 68.77%, ranking 16th out of 122 QDII equity funds, placing it in the top 13.11% [2]. Group 3: Valuation Metrics - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.19, which is in the 9.23rd percentile over the past three years, indicating a valuation lower than 90.77% of the historical data [2]. Group 4: Sector Composition - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.72% of the index, including companies like Innovent Biologics, BeiGene, and WuXi Biologics [3][5]. - The top stocks have shown varied performance, with notable increases in companies like XinDa Biologics (+6.12%) and Kangfang Biologics (+6.95%) [5]. Group 5: Industry Outlook - According to Xiangcai Securities, the domestic innovative drug industry is expected to reach a turning point in 2025, shifting from capital-driven to profit-driven growth, presenting opportunities for both performance and valuation recovery [6]. - The commercialization of innovative products and the acceleration of research outcomes are expected to support market recovery [6].

Group 1 - Hong Kong innovative drug concept stocks saw significant gains in early trading, with companies like Ascentage Pharma-B, CanSino Biologics, Kelun-Biotech, and Zai Lab rising over 5% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net inflow of over 17 million yuan recently, reaching a historical high in scale, with nearly 200 million yuan added in June alone [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index announced a revision to its compilation scheme, focusing solely on innovative drug companies, achieving a 100% "purity" in its index [1] Group 2 - Major multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China, with the procurement amount from January to May nearing the total for the entire year of 2024, indicating the competitiveness of China's innovative drugs in the international market [2] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with its scale surpassing 400 million yuan, providing investors with opportunities in the innovative drug industry [2]

Core Insights - The Chinese innovative drug sector is experiencing significant growth, particularly in overseas markets, marking a pivotal moment in 2025 as it gains global competitiveness [1] - The Hong Kong stock market's innovative drug index has shown impressive returns, making it a standout performer in the first half of 2025 [1] Group 1: Innovative Drug Development - Business Development (BD) refers to the strategic efforts to expand a company's market presence, while License-out is a key form of BD involving the authorization of drug rights to multinational companies [2] - The number and value of License-out transactions by Chinese pharmaceutical companies have been on the rise, reaching a historical peak of $52.3 billion in 2024, with $4.1 billion in upfront payments [5] - A notable example includes the collaboration between Innovent Biologics and Pfizer, which set a record with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion for a PD-1/VEGF bispecific antibody [7] Group 2: Market Dynamics - The global innovative drug market is vast, with China accounting for only 3% while the U.S. dominates with over 50%, making U.S. market entry crucial for Chinese companies [8] - The New-Co model, which involves forming new companies to attract external investment for drug development, is gaining traction in China, contrasting with the License-out model [8] Group 3: Industry Events and Trends - Major international oncology conferences such as ASCO, AACR, and ESMO serve as critical platforms for pharmaceutical companies to showcase their innovations and gauge industry trends [9] - At the 2025 ASCO conference, Chinese researchers led over 70 abstracts, a historic high compared to just one a decade ago, indicating a rapid advancement in the sector [11] Group 4: Drug Classification - First-in-class (FIC) drugs represent the highest value in innovative pharmaceuticals, while other categories include Best-in-class and Me-better, which are variations of existing drugs [12] - Chinese innovative drugs have achieved FIC breakthroughs in areas like bispecific antibodies and ADCs, positioning them as leaders in specific niches [12] Group 5: Investment Landscape - The introduction of Chapter 18A by the Hong Kong Stock Exchange allows unprofitable biotech companies to list, attracting numerous mainland innovative drug firms [27] - The A-share market has seen a relatively subdued performance in innovative drugs compared to Hong Kong, but there is potential for growth as more unprofitable yet promising companies may list on the STAR Market [29]

Market Overview - The Hang Seng Index (HSI) has shown a strong performance over the past six months, starting at 19,600 and reaching a high of 24,800, with a current level around 24,200, indicating a fluctuation of over 5,000 points [1] - The pharmaceutical sector has been the best-performing industry, with notable stocks like Kangfang Biotech (9926), China Biologic Products (1177), and WuXi Biologics (2269) showing exceptional gains [1] - Technology stocks, particularly Xiaomi (01810), have also performed well, with a 74% increase, while NetEase (09999) and Kuaishou (01024) saw gains of 50% and 48%, respectively [1] IPO and Derivative Market - The overall Hong Kong stock market has strengthened significantly in the first half of the year compared to 2023, with notable IPOs such as CATL and increased interest in consumer stocks like Pop Mart (9992) [2] - The issuance of structured products has been active, with the market responding to stock price movements, particularly for high-performing stocks [2] Investment Signals - The current sentiment in the market shows a bullish outlook, with 70% of investors holding bullish positions in HSI bull certificates, while 30% are bearish [5] - Caution is advised as the market lacks strong momentum, and there may be a potential pullback to around 23,700 before any further upward movement [5] Stock Analysis - Xiaomi has recently launched a new product, the YU7 car, which received 200,000 orders within an hour, driving its stock price to around 61, marking a 74% increase in the first half of the year [9] - BYD's sales in June reached 382,000 vehicles, with stock prices showing resilience around the 120 mark, indicating potential for further gains [13] - China Construction Bank has seen its stock price rise above 8, with a strong buy signal indicated for its derivatives [16] - China General Nuclear Power (01816) has shown a steady upward trend, with a buy signal for its structured products [19]